Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A mid-stage trial of the experimental drug islatravir plus Pifeltro did not see notable shifts in measures of kidney function.
Plus: Watch a video interview series exploring the intersections between HIV and COVID-19.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
A long-term study found that kidney transplants between people with HIV have high success rates.
Rates of HIV acquisition were very low among people taking Descovy or Truvada, but Descovy had less effect on kidneys and bones.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.
A long-term study also found that superinfection—acquiring a second strain of HIV—was not a risk for the transplantees.
Study finds the two types of stroke, ischemic and hemorrhagic, have different risk factors.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
Researchers compared data on more than 9,000 people with HIV who took either version of tenofovir.
A new analysis also found a correlation between higher adherence to the daily drug regimen and greater bone density loss.
Truvada and Descovy are both highly effective and generally safe options for HIV prevention.
A decade of aging brings on heart and kidney troubles in people with HIV.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.